FiercePharma: As Adderall shortages persist, Takeda's rival Vyvanse is now in short supply
Takeda says the situation affects its 40-mg, 60-mg and 70-mg dosage strengths of Vyvanse. The 40-mg dose supply "will dip in mid-June and will be replenished in a few weeks," according to Takeda's ...
As Adderall shortages persist, Takeda's rival Vyvanse is now in short supply
Drugmakers have begun shipping copycat versions of Takeda Pharmaceutical's drug Vyvanse, which is expected to offset the ongoing shortage of the ADHD medicine in the United States. The U.S. Food and ...
Benzinga.com: Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production
Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production
FiercePharma: Takeda, still in a Vyvanse slog, lifts guidance as it looks to new wave of growth
Quarter after quarter for the past year, Takeda’s revenues have been bogged down by generic impacts to its stalwart ADHD med Vyvanse. Now that the gap between Vyvanse erosion and growth from new ...
Takeda, still in a Vyvanse slog, lifts guidance as it looks to new wave of growth
FiercePharma: Takeda wades through more Vyvanse declines, muses DTC model as US pricing uncertainty looms
Takeda, coming off a high of 2024 growth, is pushing through what it says will be the worst of its Vyvanse-related declines. The company’s quarterly revenues from April to June sank 8.4% to 1.1 ...
Takeda wades through more Vyvanse declines, muses DTC model as US pricing uncertainty looms
Morningstar: Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three ...